{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:22Z","timestamp":1791233062202,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00342528"],"award-info":[{"award-number":["RS-2024-00342528"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00213596"],"award-info":[{"award-number":["RS-2023-00213596"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04145-6","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T04:53:05Z","timestamp":1756961585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cytotoxic CD4\u207a T cells exhibit an immunosuppressive shift in checkpoint immunotherapy resistance in melanoma patients"],"prefix":"10.1007","volume":"74","author":[{"given":"Heekyong R.","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeongchan","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungho","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suntae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"4145_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:989\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.001","journal-title":"Immunity"},{"key":"4145_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ (2022) Managing the TME to improve the efficacy of cancer therapy. Front Immunol 13:954992. https:\/\/doi.org\/10.3389\/fimmu.2022.954992","journal-title":"Front Immunol"},{"key":"4145_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, Gogenur I (2021) Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer 124:359\u2013367. https:\/\/doi.org\/10.1038\/s41416-020-01048-4","journal-title":"Br J Cancer"},{"key":"4145_CR4","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11:3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"Nat Commun"},{"key":"4145_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H (2019) Regulatory t cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol 16:356\u2013371. https:\/\/doi.org\/10.1038\/s41571-019-0175-7","journal-title":"Nat Rev Clin Oncol"},{"key":"4145_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8:523\u2013532. https:\/\/doi.org\/10.1038\/nri2343","journal-title":"Nat Rev Immunol"},{"key":"4145_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S (2023) Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 41:450\u2013465. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.014","journal-title":"Cancer Cell"},{"key":"4145_CR8","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L (2021) Cytotoxic CD4(+) T cells in cancer: expanding the immune effector toolbox. Immunity 54:2701\u20132711. https:\/\/doi.org\/10.1016\/j.immuni.2021.11.015","journal-title":"Immunity"},{"key":"4145_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00194","volume":"8","author":"A Takeuchi","year":"2017","unstructured":"Takeuchi A, Saito T (2017) CD4 CTL, a cytotoxic subset of CD4(+) T cells, their differentiation and function. Front Immunol 8:194. https:\/\/doi.org\/10.3389\/fimmu.2017.00194","journal-title":"Front Immunol"},{"key":"4145_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867189","volume":"13","author":"M Cenerenti","year":"2022","unstructured":"Cenerenti M, Saillard M, Romero P, Jandus C (2022) The era of cytotoxic CD4 T cells. Front Immunol 13:867189. https:\/\/doi.org\/10.3389\/fimmu.2022.867189","journal-title":"Front Immunol"},{"key":"4145_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nri.2015.18","volume":"16","author":"M DuPage","year":"2016","unstructured":"DuPage M, Bluestone JA (2016) Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol 16:149\u2013163. https:\/\/doi.org\/10.1038\/nri.2015.18","journal-title":"Nat Rev Immunol"},{"key":"4145_CR12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175:998\u20131013. https:\/\/doi.org\/10.1016\/j.cell.2018.10.038","journal-title":"Cell"},{"key":"4145_CR13","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun D et al (2021) TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res 49:D1420\u2013D1430. https:\/\/doi.org\/10.1093\/nar\/gkaa1020","journal-title":"Nucleic Acids Res"},{"key":"4145_CR14","doi-asserted-by":"publisher","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","volume":"51","author":"Y Han","year":"2023","unstructured":"Han Y et al (2023) TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res 51:D1425\u2013D1431. https:\/\/doi.org\/10.1093\/nar\/gkac959","journal-title":"Nucleic Acids Res"},{"key":"4145_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2022.05.001","volume":"247","author":"T Preglej","year":"2022","unstructured":"Preglej T, Ellmeier W (2022) CD4(+) cytotoxic T cells - phenotype, function and transcriptional networks controlling their differentiation pathways. Immunol Lett 247:27\u201342. https:\/\/doi.org\/10.1016\/j.imlet.2022.05.001","journal-title":"Immunol Lett"},{"key":"4145_CR16","doi-asserted-by":"publisher","first-page":"1271236","DOI":"10.3389\/fimmu.2023.1271236","volume":"14","author":"A Malyshkina","year":"2023","unstructured":"Malyshkina A, Bruggemann A, Paschen A, Dittmer U (2023) Cytotoxic CD4(+) T cells in chronic viral infections and cancer. Front Immunol 14:1271236. https:\/\/doi.org\/10.3389\/fimmu.2023.1271236","journal-title":"Front Immunol"},{"key":"4145_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada SA et al (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207:637\u2013650. https:\/\/doi.org\/10.1084\/jem.20091918","journal-title":"J Exp Med"},{"key":"4145_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1084\/jem.20091921","volume":"207","author":"Y Xie","year":"2010","unstructured":"Xie Y et al (2010) Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207:651\u2013667. https:\/\/doi.org\/10.1084\/jem.20091921","journal-title":"J Exp Med"},{"key":"4145_CR19","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY et al (2020) Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181:1612\u20131625. https:\/\/doi.org\/10.1016\/j.cell.2020.05.017","journal-title":"Cell"},{"key":"4145_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s42003-023-04812-3","volume":"6","author":"W Lin","year":"2023","unstructured":"Lin W et al (2023) Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice. Commun Biol 6:447. https:\/\/doi.org\/10.1038\/s42003-023-04812-3","journal-title":"Commun Biol"},{"issue":"91","key":"4145_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi9517","volume":"9","author":"EG Bawden","year":"2024","unstructured":"Bawden EG et al (2024) CD4(+) t cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses. Sci Immunol 9(91):eadi9517. https:\/\/doi.org\/10.1126\/sciimmunol.adi9517","journal-title":"Sci Immunol"},{"key":"4145_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3348","author":"A Cachot","year":"2021","unstructured":"Cachot A et al (2021) Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.abe3348","journal-title":"Sci Adv"},{"key":"4145_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay RE, Richardson EK, Toh HC (2021) Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther 28:5\u201317. https:\/\/doi.org\/10.1038\/s41417-020-0183-x","journal-title":"Cancer Gene Ther"},{"key":"4145_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira G et al (2022) Landscape of helper and regulatory antitumour CD4(+) T cells in melanoma. Nature 605:532\u2013538. https:\/\/doi.org\/10.1038\/s41586-022-04682-5","journal-title":"Nature"},{"key":"4145_CR25","doi-asserted-by":"publisher","first-page":"875718","DOI":"10.3389\/fimmu.2022.875718","volume":"13","author":"Q Liu","year":"2022","unstructured":"Liu Q et al (2022) Tumor-specific CD4(+) T cells restrain established metastatic melanoma by developing into cytotoxic CD4(-) T cells. Front Immunol 13:875718. https:\/\/doi.org\/10.3389\/fimmu.2022.875718","journal-title":"Front Immunol"},{"key":"4145_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B et al (2023) CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618:1033\u20131040. https:\/\/doi.org\/10.1038\/s41586-023-06199-x","journal-title":"Nature"},{"key":"4145_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.trecan.2023.07.013","volume":"9","author":"K Wu","year":"2023","unstructured":"Wu K, Fong L (2023) CD4(+) T cells help myeloid-mediated killing of immune-evasive tumors. Trends Cancer 9:777\u2013779. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.013","journal-title":"Trends Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04145-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04145-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:03:48Z","timestamp":1758729828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04145-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04145-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Heekyong R. Bae is affiliated with Omixplus, LLC and Suntae Kim serves as its Chief Executive Officer. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"297"}}